Navigation Links
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:7/7/2013

ALISO VIEJO, Calif., July 5, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that on July 2, 2013, the Company approved the grant of stock options to new employees to purchase 91,500 shares of common stock in the aggregate.  The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4).

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Avanir granted to 21 new employees an option to purchase shares of Avanir's common stock with an exercise price equal to $4.54, the closing price per share of Avanir's common stock as reported by NASDAQ on July 2, 2013, the date of grant.  Each of the options is a non-qualified option and will vest one-quarter of the underlying shares on the first anniversary of the grant date and then with respect to the remaining shares quarterly thereafter over the following three years, assuming in each case the employee remains continuously employed by Avanir.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com 
+1 (949) 389-6700


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals To Present at Three Conferences In May
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Md. , and GAITHERSBURG, Md. , ... XON ), a leader in the engineering and industrialization ... of the planet, today announced that it has entered into ... GNVC ), a clinical-stage company and pioneer in ... Intrexon intends to integrate and expand upon GenVec,s expertise in ...
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... "Acidity Regulators Market - Global Opportunity Analysis and Industry ... valued at $4,456 million in 2015, and is expected to reach ... 2016 to 2022. Asia-Pacific generated the highest ... by North America and Europe ...
(Date:1/24/2017)... Jan. 24, 2017 Mezzion has filed a ... State court alleging that Dr. Reddy,s committed fraud relating ... and Drug Administration (FDA) cGMP practices, and misrepresenting its ... repeatedly represented to Mezzion that it was compliant with ... Mezzion.  The suit also states that Dr. Reddy,s misconduct ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... i2i Population Health, a national leader in population health management (PHM) technology, ... financial background is an excellent fit for i2i,” says Justin Neece, president. “He’s that ... need to take the company to the next level of growth.” , McNamara ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired ... its 12th year in 2017. The entrepreneurs will showcase their businesses on February ...
(Date:1/24/2017)... Philadelphia, PA (PRWEB) , ... January 24, 2017 , ... ... America, but the co-founder of the organization End Distracted Driving , Joel Feldman, ... Today. , Feldman's story was featured in one of the top newspapers in circulation ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical economic ... the Frank Hawkins Kenan Institute of Private Enterprise at the University ... makers identified concrete solutions at the “What’s Next, America?” conference at the Kenan ...
(Date:1/24/2017)... ... 24, 2017 , ... The NewKILO JRP, a three-year project of the European ... European Union (EU), was completed in May 2015. The future definition will require the ... in air, which presents some challenges to establishing traceability to the mass scale. , ...
Breaking Medicine News(10 mins):